Apixaban Dosing and Management for Acute Deep Vein Thrombosis

Initial (Loading) Phase – Days 1‑7

• Give apixaban 10 mg orally twice daily for the first 7 days to achieve rapid anticoagulation without any preceding parenteral heparin or LMWH. This regimen was validated in the AMPLIFY phase‑III trial (5,395 participants) showing non‑inferiority to enoxaparin/warfarin and a markedly lower major‑bleeding rate (0.6 % vs 1.8 %). Evidence level: high‑quality RCT. 1

Maintenance Phase – After Day 7

• Switch to apixaban 5 mg orally twice daily after the loading period and continue for at least 3 months in patients with provoked DVT. Evidence level: guideline recommendation based on trial data. 2

Extended‑Phase Anticoagulation (Beyond 6 Months)

• For patients who require continued anticoagulation after 6 months, reduce the dose to 2.5 mg orally twice daily for secondary prevention. This lower dose maintains efficacy while reducing bleeding risk. Evidence level: moderate (clinical trial subgroup analysis). 3

Dose‑Reduction Criteria (Specific to Atrial Fibrillation)

• The standard dose‑reduction criteria for apixaban (age ≥ 80 yr, weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL) do not apply to DVT treatment; no dose reduction is needed during the initial or maintenance phases. Guideline clarification. 3

Contraindications and Cautions

• Avoid apixaban in patients with severe renal impairment (creatinine clearance < 15 mL/min).
• Use caution when creatinine clearance is < 25 mL/min, as such patients were excluded from pivotal trials.
• Avoid in significant hepatic impairment (transaminases > 2 × ULN or bilirubin > 1.5 × ULN). Evidence level: expert consensus based on pharmacokinetic data. 5

Safety Advantage Over Traditional Therapy

• Apixaban’s fixed‑dose regimen eliminates routine INR monitoring and the need for initial heparin bridging, simplifying treatment. Guideline recommendation. 2
• Compared with enoxaparin/warfarin, apixaban achieved a 69 % relative risk reduction in major bleeding (RR 0.31; 95 % CI 0.17‑0.55). Evidence level: high (AMPLIFY trial). 1

Cancer‑Associated DVT

• Although cancer patients comprised only ~2.7 % of the AMPLIFY cohort, apixaban is now considered a viable option for cancer‑associated DVT. Guideline update. 5
• Recent data demonstrate that apixaban is non‑inferior to dalteparin for treating cancer‑associated venous thromboembolism. Evidence level: moderate (comparative trial).* 6

Practical Pitfalls to Avoid

• Do not apply atrial‑fibrillation dose‑reduction criteria to acute DVT treatment; the 2.5 mg twice‑daily dose is reserved for extended secondary prevention only. Guideline clarification. 3
• Do not use heparin bridging when initiating apixaban; the loading dose provides immediate anticoagulation. Guideline recommendation. 2